Onconetix Faces Delisting Concerns

Ticker: ONCO · Form: 8-K · Filed: 2024-12-12T00:00:00.000Z

Sentiment: bearish

Topics: delisting, listing-rules, company-name-change

TL;DR

Onconetix might get delisted, former names include Blue Water Biotech.

AI Summary

Onconetix, Inc. filed an 8-K on December 12, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc. The filing also includes other events and financial statements and exhibits.

Why It Matters

This filing indicates potential issues with Onconetix, Inc.'s ability to remain listed on its exchange, which could significantly impact its stock value and liquidity.

Risk Assessment

Risk Level: high — The filing explicitly mentions a notice of delisting or failure to satisfy continued listing rules, indicating significant financial or operational distress.

Key Players & Entities

FAQ

What specific rule or standard has Onconetix, Inc. failed to satisfy, leading to the notice of delisting?

The provided text does not specify the exact rule or standard that Onconetix, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on December 6, 2024.

What were the previous names of Onconetix, Inc.?

Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.

What is the primary business of Onconetix, Inc. according to its SIC code?

According to its Standard Industrial Classification (SIC) code, Onconetix, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry.

What is the filing date of this 8-K report?

This 8-K report was filed on December 12, 2024.

Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-12-12 17:05:10

Key Financial Figures

Filing Documents

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On December 6, 2024, Onconetix, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q") with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC. On December 10, 2024, the Company filed its Form 10-Q with the SEC. This Current Report on Form 8-K is filed to satisfy the obligation under Item 3.01(a) of Form 8-K that the Company publicly disclose the deficiency within four (4) business days after the date of the deficiency letter.

01. Other Events

Item 8.01. Other Events. On December 12, 2024, the Company issued a press release announcing its receipt of the Notice. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Press Release, dated December 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCONETIX, INC. Date: December 12, 2024 By: /s/ Karina M. Fedasz Name: Karina M. Fedasz Title: Interim Chief Financial Officer 2

View on Read The Filing